Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)

Günter Emons*, Grigor Gorchev, Jalid Sehouli, Pauline Wimberger, Anne Stähle, Lars Hanker, Felix Hilpert, Herbert Sindermann, Carsten Gründker, Philipp Harter

*Corresponding author for this work
19 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

INIS

Pharmacology, Toxicology and Pharmaceutical Science